No abstract

No abstract

Background. Apart from surgery and medications, radiation therapy is one of the main treatment methods for malignant tumors of the cervix. However, its use is associated with high incidence of urological complications. In addition, the need for long-term treatment, reduced level of patients’ quality of life promote the necessity to minimize the frequency of urological complications and justify search and study of the most adequate methods of their prevention.Aim. To evaluate the effect of radioprotector sodium deoxyribonucleate on clinical characteristics and quality of life of patients with cervical cancer after radiation treatment.Materials and methods. 80 patients with cervical cancer treated in A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary. Patients received chemoand radiotherapy with the 3D conformal radiotherapy method in combination with intracavity gamma therapy sources of high dose with subsequent application of radioprotector and without it.Results. On the 3rd visit it was found that in patients with cervical cancer using a radioprotector, reduced red blood cells and flat epithelium cells content in the urine sediment, it may be due to the reparative and cytoprotective sodium deoxyribonucleate properties. In the assessment of the life quality after combined therapy completion with radioprotector, 60 % of patients’ responses to the health assessment questions of the last week differed from the comparison group. Undesirable phenomena associated with sodium deoxyribonucleate therapy not observed in cervical cancer patients during radiotherapy and subsequent observation period.Conclusion. Conformal external beam radiation therapy in combination with long-term intramuscular administration of a radioprotector has advantages compared to 3D conformal radiation therapy. This method reduces the severity of post-radiation side effects, increases time to development of hematological toxicity in the context of combination chemoradiotherapy, and reduces urothelial damage caused by chemoradiotherapy.

No abstract

No abstract

государственный медицинский университет имени проф. В. Ф. Войно-Ясенецкого Министерства здравоохранения РФ, ректор -д. м. н., проф. И. П. Артюхов; кафедра офтальмологии с курсом ПО имени проф. М. А Дмитриева,зав. -д. м. н. Е. В. Козина; 2 КГБУЗ Красноярский краевой клинический онкологический диспансер имени А. И. Крыжановского, гл. врач -к. м. н. А. А. Модестов. p%'>,%. В обзоре представлены сведения об эпидемиологических особенностях увеальной меланомы в различных странах мира, России. Проанализированы показатели заболеваемости у больных меланомой сосудистой оболочки. Представлены основные факторы риска развития данного заболевания, в том числе демографические и факторы, связанные с образом жизни. j+>7%";% 1+." : увеальная меланома, эпидемиология, заболеваемость, факторы риска.

краевой клинический онкологический диспансер им. А. И. Крыжановского»; 1 ФГБОУ ВО Красноярский государственный медицинский университет имени проф. В. Ф. Войно-Ясенецкого, p%'>,%. Рак мочевого пузыря входит в число ведущих онкоурологических заболеваний. Изучение нарушений регулирования фаз клеточного цикла способно предоставить ценные данные по биологии развития данного заболевания. В представленной работе проведено сравнение распределения клеток по различным фазам клеточного цикла у больных раком мочевого пузыря в опухолевой и неизмененной ткани. Обнаружено, что основная часть клеток находится в синтетической фазе. Кроме того, в опухолевой ткани больше клеток находится в пресинтетической фазе и фазе покоя. j+>7%";% 1+." : рак мочевого пузыря, уротелиальный рак, клеточный цикл, пролиферация.

Results: To develop a method for reducing the frequency and severity of early radiation reactions in patients with cancer of the uterus or cervix. Material and methods: We analyzed the results of treatment of 60 patients with cancer of the uterus and cervix, patients received a postoperative course of external beam radiotherapy combined with the intramuscular administration of the Derinat® radioprotector (sodium deoxyribonucleate); in the second arm, they received a postoperative course of external beam radiotherapy and standard therapy in case of radiation cystitis. The assessment of radiation reactions severity was performed with the EORTC QLQ-C30 criteria, WBC count, IPSS scale, urine analysis and cystoscopic examination evaluated with the developed by us scale. Results: Evaluation of the quality of life in patients with cervical or uterine cancer at the final stage of treatment using the IPSS scale showed that in the arm of patients with sodium deoxyribonucleate, there was a 30.4 % (p> 0.05) decrease in the symptoms of urinary disorders. The use of the radioprotector sodium deoxyribonucleate also statistically significantly reduced the incidence of radiation cystitis by 73 %. According to cystoscopy, the total bladder injury score at the end of treatment was 147 % lower. The number of leukocytes in the urine analysis at the end of treatment was 116.3 % lower (p≤0.01) in those who received sodium deoxyribonucleate Conclusion: The data obtained indicate the radioprotective efficacy of sodium deoxyribonucleate and make it possible to recommend its intramuscular administration to patients with cancer of the uterus and cervix against the background of external beam radiation therapy to reduce the frequency and severity of acute radiation cystitis in patients with cancer of the uterus or cervical cancer receiving external beam radiation therapy.